![](/img/cover-not-exists.png)
400 MODELING, CLINICAL AND VIROLOGY DATA FROM PHASE 2 AND 3 STUDIES SUPPORT 12-WEEK TELAPREVIR DURATION IN COMBINATION WITH 24- OR 48-WEEK PEGINTERFERON/RIBAVIRIN DURATION
B. Adiwijaya, T.L. Kieffer, D.J. Bartels, G. Picchio, S. De Meyer, K. Eisenhauer, M. Beumont, N. Adda, C.I. Wright, R.S. Kauffman, V. GargVolume:
54
Year:
2011
Language:
english
DOI:
10.1016/s0168-8278(11)60402-9
File:
PDF, 145 KB
english, 2011